ClinicalTrials.gg
Sign In

Wet Macular Degeneration clinical trials

The registry lists 93 studies for Wet Macular Degeneration across more than 10 countries. 10 are recruiting or about to start. 61 of them are mainly about Wet Macular Degeneration (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-27.

Get an email when these change. Save the Wet Macular Degeneration studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
59
Recruiting
8
Status unknown
8
Active, not recruiting
8
Terminated
6
Withdrawn
2

Phase

Phase 2
29
Phase 3
26
Phase 4
16
Phase 1
9
Early Phase 1
1

Where

United States
49
Germany
16
United Kingdom
14
Spain
14
France
13
Italy
12

Who runs them

Novartis Pharmaceuticals (14) · Bayer (8) · Outlook Therapeutics, Inc. (5) · AbbVie (4) · 4D Molecular Therapeutics (3) · Adverum Biotechnologies, Inc. (3) · EyeBiotech Ltd. (2) · Centre Hospitalier Intercommunal Creteil (2)

What is being tested here

Drugs under test in Wet Macular Degeneration studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
EYE201222
Tissue Plasminogen Activator122
Doxycycline101
Ranibizumab0110
Aflibercept019
Brolucizumab058
Bevacizumab056
Faricimab022
Dorzolamide-timolol combination012
Triamcinolone Acetonide002

Drug classes tested here Angiogenesis inhibitors 26 · Corticosteroids 3

Coming up

8phase 3 studies under way
6studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 (63%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 8
AgeWomenMen
100 (0%)0 (0%)
181 (13%)1 (13%)
301 (13%)1 (13%)
401 (13%)1 (13%)
508 (100%)8 (100%)
658 (100%)8 (100%)
758 (100%)8 (100%)
858 (100%)8 (100%)

Across all 93 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 5% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Wet Macular Degeneration studies take

Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 323 mo18–50 · 16 studies——
Phase 430 mo17–38 · 12 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 93. Browse all 93 → or search them.